What are the major opportunities in the Next Generation Immunotherapies market? What are the strategies for the Next Generation Immunotherapies market?

For detailed insights on the major opportunities and strategies in the Next Generation Immunotherapies market, Read More

How does the Next Generation Immunotherapies market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the Next Generation Immunotherapies market growth and SWOT analysis of the Next Generation Immunotherapies industry, Read More

Global Next Generation Immunotherapies Market Report 2025

Item added to cart!

Published : December 2025

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF

Purchase This Report

Next Generation Immunotherapies Global Market Report 2025

Name: Next Generation Immunotherapies Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Drug Class (Monoclonal Antibodies, Antibody-Drug Conjugates - ADC's, Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors), By Route Of Administration (Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral), By Distribution Channel (Hospital Pharmacies, Clinical Pharmacies, Other Distribution channels) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Next Generation Immunotherapies Market Overview

• Next Generation Immunotherapies market size has reached to $133.81 billion in 2024

• Expected to grow to $235.85 billion in 2029 at a compound annual growth rate (CAGR) of 12%

• Growth Driver: Rising Cancer Prevalence Driving Growth In The Market

• Market Trend: Innovative CAR T-Cell Therapy Revolutionizes Cancer Treatment In India

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Next Generation Immunotherapies Market?

Next-generation immunotherapies refer to advanced treatments designed to enhance the body's immune system to fight diseases, particularly cancer, with improved precision, efficacy, and safety. These therapies go beyond traditional immune-based treatments by leveraging cutting-edge technologies and aim to overcome earlier immunotherapies' limitations, reduce side effects, and offer long-lasting immune responses.

The main drug classes in the next-generation immunotherapies are monoclonal antibodies, antibody-drug conjugates (ADCs), angiotensin-converting enzyme (ACE) inhibitors, and immune checkpoint inhibitors. Monoclonal antibodies are lab-engineered proteins designed to precisely target specific antigens, enhancing immune response and treatment effectiveness. These drugs are administered through various routes, including intravenous, parenteral, intratumoral, subcutaneous, and oral. They are distributed through multiple channels, such as hospital pharmacies, clinical pharmacies, and other distribution channels.

Next Generation Immunotherapies Market Size and growth rate 2025 to 2029: Graph

What Is The Next Generation Immunotherapies Market Size 2025 And Growth Rate?

What Is The Next Generation Immunotherapies Market Growth Forecast?

The next generation immunotherapies market size is expected to see rapid growth in the next few years. It will grow to $235.85 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to increasing prevalence of cancer, rising healthcare expenditure, growing adoption of chimeric antigen receptor (CAR) t-cell therapy, rising burden of chronic diseases, and increasing research in the area of next-generation drugs. Major trends in the forecast period include shift toward combination therapies, technological advancements, innovation in therapeutic approaches, advancements in personalized medicine, and regulatory support advancements.

The forecast of 12.0% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of CAR-T cell therapies sourced from China and the UK, exacerbating out-of-pocket expenses and limiting access to cutting-edge cancer treatments. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Next Generation Immunotherapies Market Segmented?

1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates - ADC's, Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors

2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution channels

Subsegments:

1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies, Other Monoclonal Antibodies

2) By Antibody-Drug Conjugates (ADC's): HER2-targeted ADCs, CD30-targeted ADCs, CD19-targeted ADCs, Other ADCs

3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications

4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors, Other Immune Checkpoint Inhibitors

What Is Driving The Next Generation Immunotherapies Market? Rising Cancer Prevalence Driving Growth In The Market

The increasing prevalence of cancer is expected to propel the growth of the next-generation immunotherapies market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The prevalence of cancer is due to factors such as aging populations, lifestyle changes, environmental exposures, and improved detection methods. Next-generation immunotherapies provide advanced, targeted treatments that enhance the body's immune response to cancer, offering greater effectiveness, durability, and personalization. For instance, in May 2024, according to the reports published by the National Cancer Institute (NCI), a US-based government agency, in 2022, nearly 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally, with projections for 2040 estimating 29.9 million new cases and 15.3 million cancer-related deaths. Therefore, the increasing prevalence of cancer is driving the growth of next-generation immunotherapies market.

Who Are The Major Players In The Global Next Generation Immunotherapies Market?

Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

What Are The Key Trends Of The Global Next Generation Immunotherapies Market? Innovative CAR T-Cell Therapy Revolutionizes Cancer Treatment In India

Major companies operating in the next-generation immunotherapies market are focusing on developing innovative therapies, such as CAR T-cell therapy, to treat cancers, autoimmune diseases, and infectious diseases. CAR T-cell therapy is a type of immunotherapy where a patient's T cells (a type of immune cell) are genetically engineered to express chimeric antigen receptors (CARs). For instance, in January 2025, Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, launched Qartemi, an India's first CAR T-cell therapy. This therapy is for adult B-cell non-Hodgkin lymphoma, genetically modifying a patient's immune cells to target and destroy cancer cells, offering a highly effective and personalized treatment option. It provides renewed hope to patients for whom conventional treatments have proven ineffective, with the advantage of being more affordable than similar global options.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Next Generation Immunotherapies Market? Coherus BioSciences Acquires Surface Oncology To Strengthen Immuno-Oncology Portfolio

In September 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, acquired Surface Oncology Inc. for an undisclosed amount. With this acquisition, Coherus BioSciences aims to expand its immuno-oncology portfolio by introducing novel therapies that target the tumor microenvironment to enhance cancer treatment. Surface Oncology Inc. is a US-based immuno-oncology (I-O) company that focuses on developing next-generation immunotherapies designed to target the tumor microenvironment.

What Is The Regional Outlook For The Global Next Generation Immunotherapies Market?

North America was the largest region in the next-generation immunotherapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Next Generation Immunotherapies Market?

The next-generation immunotherapies market consists of revenues earned by entities providing services such as cell therapy manufacturing services, gene editing and engineering services, consulting services, diagnostic services, and distribution and logistics. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation immunotherapies market also includes sales of CAR-T cell therapies, natural killer (NK) cell therapies, combination therapies, and checkpoint inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Next Generation Immunotherapies Industry?

The next generation immunotherapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the next generation immunotherapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Next Generation Immunotherapies Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$150.12 billion
Revenue Forecast In 2034	$235.85 billion
Growth Rate	CAGR of 12% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The next generation immunotherapies market covered in this report is segmented – 1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates - ADC's, Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors 2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral 3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution channels Subsegments: 1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies, Other Monoclonal Antibodies 2) By Antibody-Drug Conjugates (ADC's): HER2-targeted ADCs, CD30-targeted ADCs, CD19-targeted ADCs, Other ADCs 3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications 4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors, Other Immune Checkpoint Inhibitors
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Next Generation Immunotherapies Market Characteristics

3. Next Generation Immunotherapies Market Trends And Strategies

4. Next Generation Immunotherapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Next Generation Immunotherapies Growth Analysis And Strategic Analysis Framework

5.1. Global Next Generation Immunotherapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Next Generation Immunotherapies Market Growth Rate Analysis

5.4. Global Next Generation Immunotherapies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Next Generation Immunotherapies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Next Generation Immunotherapies Total Addressable Market (TAM)

6. Next Generation Immunotherapies Market Segmentation

6.1. Global Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monoclonal Antibodies

Antibody-Drug Conjugates - ADC's

Angiotensin-Converting Enzyme (ACE) Inhibitors

Immune Checkpoint Inhibitors

6.2. Global Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intravenous

Parenteral

Intratumoral

Subcutaneous

Oral

6.3. Global Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Clinical Pharmacies

Other Distribution channels

6.4. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Anti-PD-1 Antibodies

Anti-PD-L1 Antibodies

Anti-CTLA-4 Antibodies

Anti-CD20 Antibodies

Other Monoclonal Antibodies

6.5. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Antibody-Drug Conjugates (ADC's), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

HER2-targeted ADCs

CD30-targeted ADCs

CD19-targeted ADCs

Other ADCs

6.6. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

ACE Inhibitors For Cancer Therapy

ACE Inhibitors For Other Indications

6.7. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Immune Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

PD-1 Or PD-L1 Inhibitors

CTLA-4 Inhibitors

Other Immune Checkpoint Inhibitors

7. Next Generation Immunotherapies Market Regional And Country Analysis

7.1. Global Next Generation Immunotherapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Next Generation Immunotherapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Next Generation Immunotherapies Market

8.1. Asia-Pacific Next Generation Immunotherapies Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Next Generation Immunotherapies Market

9.1. China Next Generation Immunotherapies Market Overview

9.2. China Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Next Generation Immunotherapies Market

10.1. India Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Next Generation Immunotherapies Market

11.1. Japan Next Generation Immunotherapies Market Overview

11.2. Japan Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Next Generation Immunotherapies Market

12.1. Australia Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Next Generation Immunotherapies Market

13.1. Indonesia Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Next Generation Immunotherapies Market

14.1. South Korea Next Generation Immunotherapies Market Overview

14.2. South Korea Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Next Generation Immunotherapies Market

15.1. Western Europe Next Generation Immunotherapies Market Overview

15.2. Western Europe Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Next Generation Immunotherapies Market

16.1. UK Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Next Generation Immunotherapies Market

17.1. Germany Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Next Generation Immunotherapies Market

18.1. France Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Next Generation Immunotherapies Market

19.1. Italy Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Next Generation Immunotherapies Market

20.1. Spain Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Next Generation Immunotherapies Market

21.1. Eastern Europe Next Generation Immunotherapies Market Overview

21.2. Eastern Europe Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Next Generation Immunotherapies Market

22.1. Russia Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Next Generation Immunotherapies Market

23.1. North America Next Generation Immunotherapies Market Overview

23.2. North America Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Next Generation Immunotherapies Market

24.1. USA Next Generation Immunotherapies Market Overview

24.2. USA Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Next Generation Immunotherapies Market

25.1. Canada Next Generation Immunotherapies Market Overview

25.2. Canada Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Next Generation Immunotherapies Market

26.1. South America Next Generation Immunotherapies Market Overview

26.2. South America Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Next Generation Immunotherapies Market

27.1. Brazil Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Next Generation Immunotherapies Market

28.1. Middle East Next Generation Immunotherapies Market Overview

28.2. Middle East Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Next Generation Immunotherapies Market

29.1. Africa Next Generation Immunotherapies Market Overview

29.2. Africa Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Next Generation Immunotherapies Market Competitive Landscape And Company Profiles

30.1. Next Generation Immunotherapies Market Competitive Landscape

30.2. Next Generation Immunotherapies Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Next Generation Immunotherapies Market Other Major And Innovative Companies

31.1. Bristol-Myers Squibb Company

31.2. AstraZeneca PLC

31.3. Novartis AG

31.4. GlaxoSmithKline plc (GSK)

31.5. Eli Lilly and Company

31.6. Gilead Sciences Inc.

31.7. Amgen Inc.

31.8. Boehringer Ingelheim International GmbH

31.9. Regeneron Pharmaceuticals Inc.

31.10. Incyte Corporation

31.11. BioNTech SE

31.12. Xencor Inc.

31.13. Fate Therapeutics Inc.

31.14. Immatics N.V.

31.15. Atara Biotherapeutics Inc.

32. Global Next Generation Immunotherapies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next Generation Immunotherapies Market

34. Recent Developments In The Next Generation Immunotherapies Market

35. Next Generation Immunotherapies Market High Potential Countries, Segments and Strategies

35.1 Next Generation Immunotherapies Market In 2029 - Countries Offering Most New Opportunities

35.2 Next Generation Immunotherapies Market In 2029 - Segments Offering Most New Opportunities

35.3 Next Generation Immunotherapies Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Next Generation Immunotherapies Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Next Generation Immunotherapies Market, Sub-Segmentation Of Antibody-Drug Conjugates (ADC's), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Next Generation Immunotherapies Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Next Generation Immunotherapies Market, Sub-Segmentation Of Immune Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Next Generation Immunotherapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Next Generation Immunotherapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Pfizer Inc. Financial Performance

Table 79: F. Hoffmann-La Roche Ltd. Financial Performance

Table 80: Merck & Co. Inc. Financial Performance

Table 81: AbbVie Inc. Financial Performance

Table 82: Sanofi S.A. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Next Generation Immunotherapies Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Next Generation Immunotherapies Market, Sub-Segmentation Of Antibody-Drug Conjugates (ADC's), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Next Generation Immunotherapies Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Next Generation Immunotherapies Market, Sub-Segmentation Of Immune Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Next Generation Immunotherapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Next Generation Immunotherapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Pfizer Inc. Financial Performance

Figure 79: F. Hoffmann-La Roche Ltd. Financial Performance

Figure 80: Merck & Co. Inc. Financial Performance

Figure 81: AbbVie Inc. Financial Performance

Figure 82: Sanofi S.A. Financial Performance

From Insight to Impact: Strategic Growth Mapping in the HER2-Positive Breast Cancer Market

Hospital And Nursing Home Probiotics Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Next-Gen Implantable Cardioverter Defibrillators (ICDs) : Market Forecast, Transformation, and Long-Term Trajectories

Indwelling Catheters Growth Trajectory: Key Forecasts and Strategic Insights

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Cellular Immunotherapy Global Market Report 2025 – By Therapy (Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Ce...

Therapeutic BCG Vaccines Global Market Report 2025 – By Type (Therapy BCG, Immune BCG), By Demographics (Pediatrics, Adults), By End Use (Hospitals, Clinics, Other End Users ) – Impact of Tariff and Trade War on Market S...

Natural Immune Booster Global Market Report 2025 – By Product Type (Herbal Supplements, Vitamins And Minerals, Probiotics, Functional Foods And Beverages, Essential Oils, Other Product Types), By Distribution Channel (He...

Cancer Immunotherapy Global Market Report 2025 – By Product (Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanom...

Immunoassay Global Market Report 2025 – By Product (Reagents And Kits, Analyzers Or Instruments, Software And Services), By Specimen (Blood, Saliva, Urine, Other Specimens), By Application (Therapeutic Drug Monitoring, O...

Ruminant Vaccines Global Market Report 2025 – By Vaccine Type (Inactivated Vaccines, Attenuated Or Modified Live Vaccines, Other Vaccine Types), By Indication (Bovine Respiratory Diseases (BRD), Diarrhea Or Scours, Foot-...

Immune Health Supplements Global Market Report 2025 – By Ingredients Type( Vitamins, Minerals, Herbal Botanical Extracts, Probiotics, Amino Acids, Omega 3 - Fatty Acids), By Form( Soft Gels Or Capsules, Tablets, Powder, ...

Frequently Asked Questions

What is the definition of the Next Generation Immunotherapies market?

How will the Next Generation Immunotherapies market drivers and restraints affect the market dynamics? What forces will shape the Next Generation Immunotherapies industry going forward?

The market major growth driver - Rising Cancer Prevalence Driving Growth In The Market. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Next Generation Immunotherapies market?

The next generation immunotherapies market size has grown rapidly in recent years. It will grow from $133.81 billion in 2024 to $150.12 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to rising pervasiveness of oncology, increase in research and development investments, rise in government initiatives, rising government expenditure on health, and expanding indications. The next generation immunotherapies market size is expected to see rapid growth in the next few years. It will grow to " $235.85 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to increasing prevalence of cancer, rising healthcare expenditure, growing adoption of chimeric antigen receptor (CAR) t-cell therapy, rising burden of chronic diseases, and increasing research in the area of next-generation drugs. Major trends in the forecast period include shift toward combination therapies, technological advancements, innovation in therapeutic approaches, advancements in personalized medicine, and regulatory support advancements. For further insights on this market, request a sample here

How is the Next Generation Immunotherapies market segmented?

The next generation immunotherapiesmarket covered in this report is segmented –
1) By Drug Class: Monoclonal Antibodies; Antibody-Drug Conjugates - ADC's; Angiotensin-Converting Enzyme (ACE) Inhibitors; Immune Checkpoint Inhibitors
2) By Route Of Administration: Intravenous; Parenteral; Intratumoral; Subcutaneous; Oral
3) By Distribution Channel: Hospital Pharmacies; Clinical Pharmacies; Other Distribution channels Subsegments:
1) By Monoclonal Antibodies: Anti-PD-1 Antibodies; Anti-PD-L1 Antibodies; Anti-CTLA-4 Antibodies; Anti-CD20 Antibodies; Other Monoclonal Antibodies
2) By Antibody-Drug Conjugates (ADC's): HER2-targeted ADCs; CD30-targeted ADCs; CD19-targeted ADCs; Other ADCs
3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy; ACE Inhibitors For Other Indications
4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors; CTLA-4 Inhibitors; Other Immune Checkpoint Inhibitors For further insights on this market, request a sample here

Which region has the largest share of the Next Generation Immunotherapies market? What are the other regions covered in the report?

North America was the largest region in the next-generation immunotherapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Next Generation Immunotherapies market?

What are the key trends in the Next Generation Immunotherapies market?

Major trends in this market include Innovative CAR T-Cell Therapy Revolutionizes Cancer Treatment In India. For further insights on this market, request a sample here.